News

CuraSen Presents Late-Breaking Phase 2 Data with CST-2032/CST-107 at Clinical Trials in Alzheimer’s Disease (CTAD) Conference

CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease

CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference

CuraSen Therapeutics Announces Successful Completion of Phase 2 Safety, Tolerability and Proof of Concept Study in Patients with Parkinson’s Disease or Mild Cognitive Impairment (MCI) with CST-103/CST-107 Treatment

CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease

CuraSen Therapeutics Presents Phase 1b Clinical Data with CST-103 Demonstrating Significant Increases in Cerebral Blood Flow in Patients with Mild Cognitive Impairment or Parkinson’s Disease

CuraSen Therapeutics Announces Phase 1 Clinical Data Demonstrating that Salbutamol, a Beta-2 Adrenoceptor Agonist, Significantly Increases Cerebral Perfusion, a Key Marker in Neurodegenerative Disease

CuraSen Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial with First Proprietary Compound, CST-2032, Targeting Neurodegenerative Disease

CuraSen Therapeutics Expands Management Team; Appoints Peter Butera as Senior Vice President, Operations

CuraSen Therapeutics Expands Management Team; Industry Veteran and Neuroscience Expert Gabriel Vargas, MD, PhD, Appointed to Chief Medical Officer

CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases